title: Recent advances in the development of acetyl-CoA carboxylase (ACC) inhibitors for the treatment of metabolic disease.
abstract: The development of acetyl-CoA carboxylase (ACC) inhibitors for the treatment of metabolic disease has been pursued by the pharmaceutical industry for some time. A number of recent disclosures describing potent ACC inhibitors have been reported by multiple research groups. Unlike many prior publications in this area, more recent publications contain a significant amount of in vivo efficacy data generated by long-term experiments in rodent models of metabolic disease. Additionally, one compound has been advanced to human clinical studies. The results from these studies should allow researchers to better gauge the potential utility of ACC inhibition for the treatment of human disease.
authors.affiliation: Department of Medicinal Chemistry, and Department of Molecular Structure and Characterization, Amgen, Inc. , 1 Amgen Center Drive, Thousand Oaks, California 91320, United States.
authors.forename: Matthew P
authors.initials: MP
authors.lastname: Bourbeau
authors.forename: Michael D
authors.initials: MD
authors.lastname: Bartberger
mesh_terms: D000103:Acetyl-CoA Carboxylase / Q000037:antagonists & inhibitors* / Q000737:chemistry; D000818:Animals; D004305:Dose-Response Relationship, Drug; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008659:Metabolic Diseases / Q000188:drug therapy*; D051379:Mice; D008807:Mice, Inbred BALB C; D017434:Protein Structure, Tertiary; D013329:Structure-Activity Relationship
chemical_list: D004791:Enzyme Inhibitors; D000103:Acetyl-CoA Carboxylase